OncoMed Pharmaceuticals, Inc.
OMED
OMED was delisted on the 22nd of April, 2019.
89 hedge funds and large institutions have $181M invested in OncoMed Pharmaceuticals, Inc. in 2016 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 35 increasing their positions, 14 reducing their positions, and 8 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 14
108% more call options, than puts
Call options by funds: $1.27M | Put options by funds: $611K
63% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 8
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
28% more capital invested
Capital invested by funds: $141M → $181M (+$39.8M)
6% more funds holding
Funds holding: 84 → 89 (+5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Primecap Management
Pasadena,
California
|
+$12.7M |
| 2 |
Franklin Resources
San Mateo,
California
|
+$8.15M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
+$5.5M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
+$5.12M |
| 5 |
EC
EcoR1 Capital
San Francisco,
California
|
+$3.09M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$1.7M |
| 2 |
Handelsbanken Fonder
Stockholm,
Sweden
|
-$308K |
| 3 |
NFA
Nationwide Fund Advisors
Columbus,
Ohio
|
-$233K |
| 4 |
Barclays
London,
United Kingdom
|
-$202K |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$188K |
OMED Hedge Fund Activity: Q3 2016 in Review
89 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in OncoMed Pharmaceuticals, Inc. (OMED) for Q3 2016, worth a combined $181M — up 28% from $141M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new OMED positions and 8 closed out — a net gain of 5 holders — while 35 added to existing stakes and 14 trimmed.
The largest buyer was Primecap Management, adding an estimated $12.7M. The largest seller was TFS Capital, exiting entirely with an estimated $1.7M sold.
- 89 institutional investors held OncoMed Pharmaceuticals, Inc. (OMED) as of Q3 2016, up from 84 in Q2 2016.
- Funds reported $181M of OncoMed Pharmaceuticals, Inc. stock for Q3 2016, up 28% quarter-over-quarter.
- 13 funds opened new OncoMed Pharmaceuticals, Inc. positions in Q3 2016 and 8 closed out, a net change of +5 holders.
- The largest OncoMed Pharmaceuticals, Inc. buyer in Q3 2016 was Primecap Management, an estimated $12.7M added.
- The largest OncoMed Pharmaceuticals, Inc. seller in Q3 2016 was TFS Capital, an estimated $1.7M sold.
Based on aggregated 13F filings for Q3 2016.